GSK’s (GSK) Buy Rating Reiterated at Shore Capital Group

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by analysts at Shore Capital Group in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports.

GSK has been the topic of several other reports. UBS Group reissued a “neutral” rating and set a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research report on Wednesday, January 7th. Citigroup upped their target price on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a report on Monday, February 9th. Deutsche Bank Aktiengesellschaft increased their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GSK presently has a consensus rating of “Hold” and an average price target of GBX 1,917.86.

GSK Trading Up 3.2%

GSK stock opened at GBX 2,041 on Wednesday. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,282. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82. The firm has a market capitalization of £81.87 billion, a price-to-earnings ratio of 14.70, a P/E/G ratio of 1.24 and a beta of 0.32. The company has a 50 day moving average price of GBX 2,028.25 and a 200 day moving average price of GBX 1,824.21.

GSK (LON:GSK) last announced its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Research analysts forecast that GSK will post 175.980975 EPS for the current year.

Insider Transactions at GSK

In other news, insider Jonathan Symonds bought 5,000 shares of the company’s stock in a transaction on Friday, March 20th. The shares were bought at an average cost of GBX 1,951 per share, with a total value of £97,550. Also, insider Luke Miels sold 15,579 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of GBX 2,160, for a total value of £336,506.40. In the last quarter, insiders purchased 11,447 shares of company stock valued at $24,273,097. 0.26% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.